Capital Performance Advisors’s 2seventy bio TSVT Stock Holding History

Capital Performance Advisors’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-24	Closed	-$113	–	2498
2024 Q3	$113	Buy	+24	New	+$108	﹤0.01%	2674

Other funds holding TSVT

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Capital Performance Advisors's TSVT Position: Q4 2024 in Review

Capital Performance Advisors sold out of 2seventy bio (TSVT) in Q4 2024, closing a stake of 24 shares — an estimated $113 sold.

Capital Performance Advisors first reported a position in TSVT in Q3 2024 and held it in 1 quarter. The position peaked at $113 in Q3 2024. 116 funds tracked by Wall St. Rank hold TSVT as of Q4 2024.

Capital Performance Advisors reported no remaining 2seventy bio position as of Q4 2024 after selling out during the quarter.
Capital Performance Advisors sold 24 2seventy bio shares in Q4 2024, an estimated $113.
Capital Performance Advisors first reported a position in 2seventy bio in Q3 2024 and held it in 1 quarter.
Capital Performance Advisors's 2seventy bio position peaked at $113 in Q3 2024.
116 funds tracked by Wall St. Rank held 2seventy bio as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.